Annamaria Mascolo

Sep 10, 2024 | mdpi.com | Nunzia Balzano |Annamaria Mascolo |Raffaella Di Napoli |Federica Colapietra

All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.

Jan 23, 2024 | mdpi.com | Rosanna Ruggiero |Annamaria Mascolo |Angela Spezzaferri |Claudia Carpentieri

All articles published by MDPI are made immediately available worldwide under an open access license. No specialpermission is required to reuse all or part of the article published by MDPI, including figures and tables. Forarticles published under an open access Creative Common CC BY license, any part of the article may be reused withoutpermission provided that the original article is clearly cited. For more information, please refer tohttps://www.mdpi.com/openaccess.

Nov 6, 2023 | mdpi.com | Liberata Sportiello |Raffaella Di Napoli |Nunzia Balzano |Annamaria Mascolo

All articles published by MDPI are made immediately available worldwide under an open access license. No specialpermission is required to reuse all or part of the article published by MDPI, including figures and tables. Forarticles published under an open access Creative Common CC BY license, any part of the article may be reused withoutpermission provided that the original article is clearly cited. For more information, please refer tohttps://www.mdpi.com/openaccess.

Oct 20, 2023 | mdpi.com | Nicolina Capoluongo |Annamaria Mascolo |Francesca Bernardi |Marina Sarno

1. IntroductionAntiviral therapies, when used alone, have been reported to not always be sufficient to change the course of the COronaVIrus Disease 2019 (COVID-19) [], especially in frail patients. Therefore, identifying new therapeutic options to prevent or fight this disease in its early phase is essential []. Tixagevimab–cilgavimab is a long-acting monoclonal antibody combination of two Fc-modified human monoclonal antibodies obtained from patients who recovered from COVID-19.

Oct 10, 2023 | mdpi.com | Francesca Bernardi |Annamaria Mascolo |Marina Sarno |Nicolina Capoluongo

1. IntroductionThe rapid development of coronavirus disease 2019 (COVID-19) vaccines has helped change the course of the pandemic by reducing illness severity and hospital admissions [1]. As of January 2023, the European Medicines Agency (EMA) had granted authorization to seven COVID-19 vaccines [2]. Among these, two are mRNA vaccines: BNT162b2 mRNA (produced by Pfizer-BioNTech, approved on 21 December 2020) and mRNA-1273 (Moderna, approved on 6 January 2021).